Chronic lymphocytic Leukemia Venetoclax in the First-Line with significant Survival Benefit

被引：0
|
作者：
Warpakowski, Andrea
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [1] First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
    Eichhorst, Barbara
    Niemann, Carsten U.
    Kater, Arnon P.
    Fuerstenau, Moritz
    von Tresckow, Julia
    Zhang, Can
    Robrecht, Sandra
    Gregor, Michael
    Juliusson, Gunnar
    Thornton, Patrick
    Staber, Philipp B.
    Tadmor, Tamar
    Lindstrom, Vesa
    da Cunha-Bang, Caspar
    Schneider, Christof
    Poulsen, Christian B.
    Illmer, Thomas
    Schoettker, Bjoern
    Noesslinger, Thomas
    Janssens, Ann
    Christiansen, Ilse
    Baumann, Michael
    Frederiksen, Henrik
    van der Klift, Marjolein
    Jaeger, Ulrich
    Leys, Maria B. L.
    Hoogendoorn, Mels
    Lotfi, Kourosh
    Hebart, Holger
    Gaska, Tobias
    Koene, Harry
    Enggaard, Lisbeth
    Goede, Jereon
    Regelink, Josien C.
    Widmer, Anouk
    Simon, Florian
    De Silva, Nisha
    Fink, Anna-Maria
    Bahlo, Jasmin
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl A.
    Ritgen, Matthias
    Brueggemann, Monika
    Tausch, Eugen
    Levin, Mark-David
    van Oers, Marinus
    Geisler, Christian
    Stilgenbauer, Stephan
    Hallek, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1739 - 1754
  • [2] Combination of ibrutinib and venetoclax in first-line treatment of chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (01): : 12 - 13
  • [3] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [4] First-Line Therapy for Chronic Lymphocytic Leukemia
    Cherng, Hua-Jay J.
    Jain, Nitin
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 725 - 738
  • [5] Phase 2 CAPTIVATE Results of Ibrutinib Plus Venetoclax in First-Line Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 2 - 4
  • [6] Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 Trial
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Sasaki, Koji
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Wei, Chongjuan
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William G.
    JAMA ONCOLOGY, 2021, 7 (08) : 1213 - 1219
  • [7] First-line therapy of advanced chronic lymphocytic leukemia
    Wilhelm, M
    Tony, HP
    RueckleLanz, H
    Wilms, K
    LEUKEMIA, 1997, 11 : S14 - S18
  • [8] Choosing first-line therapy for chronic lymphocytic leukemia
    Jaglowski, Samantha
    Jones, Jeffrey A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (09) : 1379 - 1390
  • [9] Real-world time to discontinuation of first-line venetoclax plus binutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023,
  • [10] Real-world time to discontinuation of first-line venetoclax plus obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, : 1227 - 1235
12345